2. Signaling Pathways
  3. JAK/STAT Signaling
    Stem Cell/Wnt
  4. STAT
  5. STAT6 Isoform

STAT6

 

STAT6 Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-100614
    AS1517499
    		Inhibitor 99.17%
    AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC50 of 21 nM.
  • HY-100754
    Ritlecitinib
    		Inhibitor 99.80%
    Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
  • HY-134771
    YM-341619
    		Inhibitor 98.01%
    YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC50=0.28 nM) without affecting Th1 cell differentiation. YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma.
  • HY-134772
    AS1810722
    		Inhibitor 98.10%
    AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.
  • HY-169179
    AK-1690
    		Degrader 99.91%
    AK-1690 is a potent and selective STAT6 PROTAC degrader. AK-1690 reduces the levels of STAT6 protein in cells (DC50=1 nM) and depletes STAT6 protein in mouse tissues. AK-1690 can be used for the research of cancer. (Pink: ligand for target protein STAT6 (HY-169182); Black: linker (HY-W459522); Blue: ligand for E3 ligase (HY-131318).
  • HY-169360
    SD-436
    		Degrader
    SD-436 is a highly selective and efficacious STAT3 PROTAC degrader (DC50: 0.5 μM), with IC50 of 19 nM (STAT3), 270 nM (STAT1), 360 nM (STAT4), >10 μM (STAT5) and >10 μM (STAT6). SD-436 promotes ubiquitination and degradation of STAT3, and induces tumor regression. SD-436 can be used for tumor research, such as leukemia and lymphoma (Pink: STAT3 ligand (HY-169361); Blue: E3 ligase ligand (HY-43722); Black: linker (HY-147052).
  • HY-158398
    STAT6-IN-4
    		Inhibitor 99.77%
    STAT6-IN-4 (Ex. 78) is a STAT6 inhibitor, with an IC50 of 0.34 μM. STAT6-IN-4 can be used in the research of diseases such as inflammatory and allergic diseases.
  • HY-158399
    STAT6-IN-5
    		Inhibitor 99.88%
    STAT6-IN-5 (compound 84) is a STAT6 inhibitor (IC50=0.24 μM), which can be used for the research of inflammatory diseases and allergic diseases (e.g. atopic dermatitis).
  • HY-N0407
    Picroside I
    		Inhibitor 99.55%
    Picroside I is the major ingredient of Picrorhiza scrophulariiflora. Picrorhiza scrophulariiflora is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma. Picroside I reduces the inflammation significantly at its higher dose. Picroside I also downregulates pSTAT6 and GATA3 expressions. Picroside I dose-dependently increases the serum levels of IFN-γ.
  • HY-112961
    Patiromer
    		Inhibitor
    Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy.
  • HY-169182
    AK-068
    AK-068 is a STAT6 ligand, with a Ki of 6 nM and at least >85-fold binding selectivity over STAT5. AK-068 is a ligand for target protein (STAT6) for PROTAC (HY-169179).
  • HY-100754C
    Ritlecitinib tosylate
    		Inhibitor 99.77%
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
  • HY-113509B
    15(R)-Lipoxin A4
    		Activator
    15(R)-Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15(R)-Lipoxin A4 can improve the phagocytic function of microglia and exhibits anti-inflammatory activity. In Alzheimer's disease (AD) mouse models, 15(R)-Lipoxin A4 improves AD-like pathology. 15(R)-Lipoxin A4 holds potential for use in inflammation and neurodegenerative disease research.
  • HY-100754A
    Ritlecitinib (malonate)
    		Inhibitor
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE).
Cat. No. Product Name / Synonyms Application Reactivity